6 tulemused
To evaluate the safety and efficacy of intra-arterial chemotherapy (IAC) for the primary or secondary treatment of infants diagnosed with advanced retinoblastoma before 3 months of age.This single-center retrospective study included 39 infants (42 eyes) OBJECTIVE
To compare outcomes of intra-arterial chemotherapy for retinoblastoma as primary therapy before (Era I) and during (Era II) the intravitreal chemotherapy era.
METHODS
In this retrospective interventional case series at a tertiary referral center, 66 eyes of 66 patients with untreated
OBJECTIVE
To determine the efficacy of rescue intra-arterial chemotherapy (IAC) for retinoblastoma recurrence following failed initial IAC.
METHODS
Retrospective, non-comparative, interventional case series of 12 eyes in 12 patients.
METHODS
Rescue IAC employed chemotherapy agents of melphalan (5mg,
OBJECTIVE
To report on our 3-year experience with the use of superselective ophthalmic artery infusion of chemotherapy as initial, primary treatment for intraocular retinoblastoma.
METHODS
Prospective, institutional review board-approved clinical trial.
METHODS
Twenty-eight eyes of 23 newly
OBJECTIVE
The aim of this study is to describe treatment outcomes and complications of selective intra-arterial chemotherapy (IAC) for intraocular retinoblastoma (RB).
METHODS
A retrospective, interventional series of 10 eyes with RB which underwent IAC using melphalan (5 mg/7.5 mg) and topotecan (1
OBJECTIVE
To analyze our 5-year experience of intra-arterial chemotherapy (IAC) for retinoblastoma as primary or secondary therapy.
METHODS
Retrospective interventional case series.
METHODS
A total of 70 eyes of 67 patients.
METHODS
Ophthalmic artery chemotherapy infusion under fluoroscopic guidance